EGFR and lung carcinoma: However, we estimate the proportion of patients with private drug insurance among all EGFR-TKI users to be low since about 70% of lung cancer patients in Quebec are diagnosed at age 65 or older, when 90% of Quebec residents are registered for public drug coverage [3,66,67].